Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections

Archives of Ophthalmology

Volumn 128, Issue 12, 2010, Pages 1523-1527

  Frenkel, Max P C ^a   Haji, Shamim A ^a,b   Frenkel, Ronald E P ^a,b  

^a Eye Research Foundation   (United States)

^b East Florida Eye Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; APRACLONIDINE; BEVACIZUMAB; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE; PEGAPTANIB; RANIBIZUMAB; TIMOLOL MALEATE;

AGED; ARTICLE; DRUG EFFECT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIHYPERTENSIVE AGENTS; APTAMERS, NUCLEOTIDE; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78650221092     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.297     Document Type: Article

References (22)

1. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640- 1642. (Pubitemid 15204559)
2. Frenkel REP, Mani L, Toler AR, Frenkel MPC. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143(6):1034-1035. (Pubitemid 46764645)
3. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27(8):1044-1047. (Pubitemid 350304005)
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
5. Hariprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol. 2006;141(1):200-201. (Pubitemid 43016199)
6. D'Amico DJ, Masonson HN, Patel M, et al; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113(6):992-1001.
7. The Brimonidine-ALT Study Group. Effect of brimonidine 0.5% on intraocular pressure spikes following 360% argon laser trabeculoplasty. Ophthalmic Surg Lasers. 1995;26(5):404-409.
8. Barnes SD, Campagna JA, Dirks MS, Doe EA. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Ophthalmology. 1999;106(10):2033-2037.
9. Tsui YP, Chiang CC, Tsai YY. Paracentesis before intravitreal injection of bevacizumab. Can J Ophthalmol. 2008;43(2):239, author reply 239-240.
10. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009;23(1):181-185.
11. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85(7):777-781. (Pubitemid 47616796)
12. Medicare Utilization for Part B. Centers for Medicare & Medicaid Services Web site. http://www.cms.gov/MedicareFeeforSvcPartsAB/04- MedicareUtilizationforPartB.asp. Accessed August 2009.
13. Lee EW, Hariprasad SM, Mieler WF, Newman TL, Apte RS. Short-term intraocular pressure trends after intravitreal triamcinolone injection. Am J Ophthalmol. 2007;143(2):365-367. (Pubitemid 46136143)
14. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology. 2006;113(7):1174-1178. (Pubitemid 43947221)
15. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(6):930-934.
16. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42(6):807-811.
17. Chang W, Chung M. Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection. Eur J Ophthalmol. 2007;17(5):776-779.
18. Dwinger MC, Pieper-Bodeewes I, Eter N, Holz FG. Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection [in German] Klin Monbl Augenheilkd. 2005;222(8):638-642. (Pubitemid 41290798)
19. Frenkel R, Mani L, Toler A. Reply, 10 October 2007. Am J Ophthalmol. 2008;145(1):186.
20. Lin JM, Tsai YY, Chiu YT, Hung PT. Paracentesis before or after intravitreal injection of triamcinolone acetonide and its necessity? Am J Ophthalmol. 2006;141(5):985-986.
21. Huang WC, Lin JM, Chiang CC, Tsai YY. Necessity of paracentesis before or after intravitreal injection of bevacizumab. Arch Ophthalmol. 2008;126(9):1314-1315.
22. Iester M, Mermoud A, Achache F, Roy S. New Tonopen XL: comparison with the Goldmann tonometer. Eye (Lond). 2001;15(pt 1):52-58.